TCF12 and neoplasm: In our study, we discovered that 8.3% of CRC patients, regardless of whether they experience tumor metastasis, have poor prognosis due to their tumor tissues expressing high TCF12 mRNA, high MALAT1, low β-catenin mRNA, and high cyclin D1 mRNA.